Total Payments
$2,390
2024 Payments
$278.88
Companies
30
Transactions
83
Medicare Patients
668
Medicare Billing
$75,971
Payment Breakdown by Category
Food & Beverage$2,390 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,390 | 83 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novocure Inc. | $856.28 | 13 | $0 (2024) |
| Monteris Medical Corporation | $199.06 | 3 | $0 (2024) |
| ABBVIE INC. | $172.48 | 7 | $0 (2022) |
| SK Life Science, Inc. | $133.84 | 3 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $125.14 | 8 | $0 (2022) |
| GENZYME CORPORATION | $96.72 | 6 | $0 (2022) |
| UCB, Inc. | $82.24 | 5 | $0 (2022) |
| Tempus AI, Inc | $74.01 | 1 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $73.70 | 3 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $66.69 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $278.88 | 8 | Novocure Inc. ($107.76) |
| 2023 | $384.69 | 5 | Novocure Inc. ($231.72) |
| 2022 | $667.54 | 22 | Novocure Inc. ($317.59) |
| 2021 | $440.85 | 23 | AbbVie Inc. ($156.61) |
| 2020 | $299.78 | 12 | SK Life Science, Inc. ($118.47) |
| 2019 | $290.49 | 11 | Novocure Inc. ($177.46) |
| 2018 | $12.72 | 1 | TESARO, Inc. ($12.72) |
| 2017 | $15.50 | 1 | Amgen Inc. ($15.50) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/16/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $85.44 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $74.01 | General |
| 02/08/2024 | Monteris Medical Corporation | Neuroblate (Device) | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: Neuroblate | ||||||
| 02/06/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $19.35 | General |
| Category: Oncology | ||||||
| 01/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $22.32 | General |
| Category: Oncology | ||||||
| 10/11/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $14.21 | General |
| 08/08/2023 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $15.47 | General |
| Category: Oncology | ||||||
| 08/02/2023 | Monteris Medical Corporation | Neuroblate (Device) | Food and Beverage | In-kind items and services | $138.76 | General |
| Category: Neuroblate | ||||||
| 06/21/2023 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $78.64 | General |
| Category: Oncology | ||||||
| 05/25/2023 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $137.61 | General |
| Category: Oncology | ||||||
| 12/08/2022 | Monteris Medical Corporation | Neuroblate (Device) | Food and Beverage | In-kind items and services | $32.64 | General |
| Category: Neuroblate | ||||||
| 11/19/2022 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $114.60 | General |
| Category: Oncology | ||||||
| 11/17/2022 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $134.47 | General |
| Category: Oncology | ||||||
| 11/10/2022 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $68.52 | General |
| Category: Oncology | ||||||
| 07/12/2022 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $31.08 | General |
| Category: Oncology | ||||||
| 07/12/2022 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Neurology | ||||||
| 06/22/2022 | EISAI INC. | Fycompa (Drug) | Food and Beverage | Cash or cash equivalent | $22.96 | General |
| Category: Neurology | ||||||
| 06/22/2022 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Musculoskeletal | ||||||
| 06/10/2022 | Avanir Pharmaceuticals, Inc. | Nuedexta (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 06/03/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: HYPERHYDROSIS | ||||||
| 05/20/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/09/2022 | Avanir Pharmaceuticals, Inc. | Nuedexta (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: pseudobulbar affect (PBA) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 44 | 88 | $36,269 | $8,775 |
| 2022 | 7 | 168 | 207 | $47,608 | $15,838 |
| 2021 | 5 | 245 | 308 | $74,320 | $28,308 |
| 2020 | 7 | 211 | 293 | $70,724 | $23,050 |
Total Patients
668
Total Services
896
Medicare Billing
$75,971
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 55 | $25,520 | $6,201 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 15 | 20 | $9,280 | $2,255 | 24.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 11 | 13 | $1,469 | $319.13 | 21.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 53 | $15,284 | $5,374 | 35.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $13,850 | $4,730 | 34.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 29 | $4,742 | $1,362 | 28.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $3,678 | $1,204 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 20 | $4,000 | $1,140 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 22 | 24 | $3,088 | $1,117 | 36.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 20 | 37 | $2,966 | $911.11 | 30.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 71 | 100 | $27,000 | $11,547 | 42.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 80 | 80 | $31,200 | $10,394 | 33.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 43 | $8,600 | $3,436 | 40.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 29 | 31 | $3,875 | $1,637 | 42.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 29 | 54 | $3,645 | $1,295 | 35.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 62 | 100 | $27,000 | $8,612 | 31.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 33 | 33 | $9,669 | $3,463 | 35.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $10,140 | $3,039 | 30.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 36 | 48 | $9,600 | $2,764 | 28.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 31 | $6,665 | $2,420 | 36.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 31 | $4,650 | $1,720 | 37.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 24 | $3,000 | $1,033 | 34.4% |
About Nawal Shaikh
Nawal Shaikh is a Neurology healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2012. The National Provider Identifier (NPI) number assigned to this provider is 1003171091.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Nawal Shaikh has received a total of $2,390 in payments from pharmaceutical and medical device companies, with $278.88 received in 2024. These payments were reported across 83 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($2,390).
As a Medicare-enrolled provider, Shaikh has provided services to 668 Medicare beneficiaries, totaling 896 services with total Medicare billing of $75,971. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neuromusculoskeletal Medicine & OMM, Neurology
- Location Fort Worth, TX
- Active Since 07/06/2012
- Last Updated 11/13/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1003171091
Products in Payments
- Optune (Device) $657.07
- Oncology (Device) $199.21
- Neuroblate (Device) $199.06
- UBRELVY (Drug) $171.03
- AUBAGIO (Drug) $116.18
- NURTEC ODT (Drug) $108.66
- Cenobamate (Drug) $103.13
- Briviact (Drug) $82.24
- NUEDEXTA (Drug) $75.15
- INGREZZA (Drug) $65.62
- Nuedexta (Drug) $49.99
- Epidiolex (Drug) $36.42
- DARZALEX (Biological) $35.61
- KEYTRUDA (Biological) $32.27
- Rubraca (Drug) $32.14
- RYBREVANT (Drug) $31.08
- ZEJULA (Drug) $28.00
- TOSYMRA (Drug) $27.42
- KYNMOBI (Drug) $25.29
- Fycompa (Drug) $22.96
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Fort Worth
Dr. Hamid Kadiwala, M.d, M.D
Neurology — Payments: $139,323
Neurology $139,323
Horacio Chiong-Rivero, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $83,086
Neurology $83,086
Sharique Ansari, M.d., Mph, M.D., MPH
Neurology — Payments: $79,831
Neurology $79,831
Krishnababu Chunduri, Md, MD
Neurology — Payments: $41,859
Neurology $41,859
Leila Bostan Shirin, M.d, M.D
Neurology — Payments: $35,690
Neurology $35,690
Jiangping Liu, Md, MD
Neurology — Payments: $33,262
Neurology $33,262